Vista Equity Partners Launches VistaOne to Expand Access to Private Software Investments
8.5.2025 09:00:00 CEST | Business Wire | Press Release
Vista Equity Partners (“Vista”), a global technology investor that specializes in enterprise software, today announced the launch of VistaOne (Lux) (“VistaOne” or the “Fund”), an open-ended investment vehicle that provides eligible non-US individual investors access to Vista’s private equity platform in a single, scaled solution.
The software sector has a projected 2027 total addressable market of $59 trillion and a growth rate of approximately 17%, making it the largest and fastest growing in the global economy.1 Yet approximately 96% of software companies are privately held and therefore inaccessible to most individual investors.2 VistaOne is one of the first software-specific evergreen private equity funds available to the private wealth market.
Founded in 2000, Vista is an operationally focused investor that pioneered a proprietary and systematic approach to value creation developed and refined over the course of 25 years and 600+ transactions. Enterprise software touches almost every sector of the global economy, covering a wide range of vertical markets and end-users, and Vista currently manages a diversified portfolio of more than 90 companies providing mission-critical software solutions to 500+ million users around the world.
VistaOne is designed to offer fully drawn exposure to direct Vista deals with one layer of fees, featuring quarterly liquidity (subject to certain conditions) and low investment minimums compared to traditional private market investment strategies. With a single commitment, eligible investors gain access to a balanced portfolio across the lifecycle of large-, mid- and small-cap private software companies through Vista’s Flagship, Foundation and Endeavor private equity strategies.
“The launch of VistaOne is another significant step forward in Vista’s efforts to expand access to private software investments by providing a compelling offering for non-US investors to diversify their portfolios and broaden exposure to a generational opportunity in Generative AI,” said David Breach, Co-CEO of VistaOne and President, Chief Operating Officer of Vista Equity Partners.
VistaOne is managed by a dedicated team of investment and operations professionals at Vista who bring decades of software and operational expertise, as well as experienced private wealth sales and client service experts who work directly with wealth managers to help their clients access the untapped opportunity in enterprise software. The Fund is available to wealth managers in Vista’s immediate network and other eligible non-US investors seeking to diversify their portfolios in private equity with a software specialist.
“VistaOne provides a streamlined and efficient evergreen solution for investors seeking to increase their allocation to some of the world’s most innovative, high-growth software companies, and do so alongside one of the largest and most experienced software investors,” said Dan Parant, Co-President of VistaOne and Managing Director, Global Head of Private Wealth Solutions at Vista Equity Partners. “We are excited to offer this differentiated vehicle to the non-US private wealth market.”
For more information about VistaOne and how to invest, please visit Vista’s Private Wealth Solutions website.
Advisors
S64, a leading global alternatives fintech and solutions partner to the wealth management industry, supported Vista in the development and launch of the Fund and will be the Platform Operator. Simpson Thacher & Bartlett LLP, a global law firm that advises many of the world’s leading and most innovative companies, served as legal counsel to Vista.
About Vista Equity Partners
Vista is a global technology investor that specializes in enterprise software. Vista’s private market strategies seek to deliver differentiated returns through a proprietary and systematic approach to value creation developed and refined over the course of 25 years and 600+ transactions. Today, Vista manages a diversified portfolio of software companies that provide mission-critical solutions to millions of customers around the world. As of September 30, 2024, Vista had more than $100 billion in assets under management. Further information is available at vistaequitypartners.com. Follow Vista on LinkedIn, @Vista Equity Partners, and on X, @Vista_Equity.
| ____________________________________ |
1 Gartner, proprietary research as of 09/2024 |
2 Gartner, proprietary research as of 09/2024 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250507768422/en/
Contacts
Media Contacts
Vista Equity Partners
Brian W. Steel
media@vistaequitypartners.com
212-804-9170
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom